Allergan (AGN -2.8%) dips on a Goldman downgrade to Neutral this morning. The firm cites a lack of near-term catalysts, saying it now sees greater upside to Forest Labs (NYSE:FRX), with its potential for significant restructuring/strategic alternatives and pending new management changes later this year.